Adeno-associated virus 9-mediated airway expression of antibody protects old and immunodeficient mice against influenza virus

Virginie S. Adam, Marco Crosariol, Sachin Kumar, Moyar Q. Ge, Sarah E. Czack, Soumitra Roy, Angela Franciska Haczku, Anna Tretiakova, James M. Wilson, Maria P. Limberis

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Influenza causes serious and sometimes fatal disease in individuals at risk due to advanced age or immunodeficiencies. Despite progress in the development of seasonal influenza vaccines, vaccine efficacy in elderly and immunocompromised individuals remains low. We recently developed a passive immunization strategy using an adeno-associated virus (AAV) vector to deliver a neutralizing anti-influenza antibody at the site of infection, the nasal airways. Here we show that young, old, and immunodeficient (severe combined immunodeficient [SCID]) mice that were treated intranasally with AAV9 vector expressing a modified version of the broadly neutralizing anti-influenza antibody FI6 were protected and exhibited no signs of disease following an intranasal challenge with the mouse-adapted H1N1 influenza strain A/Puerto Rico/8/1934(H1N1) (PR8) (Mt. Sinai strain). Nonvaccinated mice succumbed to the PR8 challenge due to severe weight loss. We propose that airway-directed AAV9 passive immunization against airborne infectious agents may be beneficial in elderly and immunocompromised patients, for whom there still exists an unmet need for effective vaccination against influenza.

Original languageEnglish (US)
Pages (from-to)1528-1533
Number of pages6
JournalClinical and Vaccine Immunology
Volume21
Issue number11
DOIs
StatePublished - Nov 1 2014
Externally publishedYes

Fingerprint

Immunization
Dependovirus
Orthomyxoviridae
Viruses
Human Influenza
Antibodies
Influenza Vaccines
Passive Immunization
Neutralizing Antibodies
Vaccines
Anti-Idiotypic Antibodies
Puerto Rico
SCID Mice
Immunocompromised Host
Nose
Weight Loss
Vaccination
Infection

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Clinical Biochemistry
  • Microbiology (medical)

Cite this

Adeno-associated virus 9-mediated airway expression of antibody protects old and immunodeficient mice against influenza virus. / Adam, Virginie S.; Crosariol, Marco; Kumar, Sachin; Ge, Moyar Q.; Czack, Sarah E.; Roy, Soumitra; Haczku, Angela Franciska; Tretiakova, Anna; Wilson, James M.; Limberis, Maria P.

In: Clinical and Vaccine Immunology, Vol. 21, No. 11, 01.11.2014, p. 1528-1533.

Research output: Contribution to journalArticle

Adam, VS, Crosariol, M, Kumar, S, Ge, MQ, Czack, SE, Roy, S, Haczku, AF, Tretiakova, A, Wilson, JM & Limberis, MP 2014, 'Adeno-associated virus 9-mediated airway expression of antibody protects old and immunodeficient mice against influenza virus', Clinical and Vaccine Immunology, vol. 21, no. 11, pp. 1528-1533. https://doi.org/10.1128/CVI.00572-14
Adam, Virginie S. ; Crosariol, Marco ; Kumar, Sachin ; Ge, Moyar Q. ; Czack, Sarah E. ; Roy, Soumitra ; Haczku, Angela Franciska ; Tretiakova, Anna ; Wilson, James M. ; Limberis, Maria P. / Adeno-associated virus 9-mediated airway expression of antibody protects old and immunodeficient mice against influenza virus. In: Clinical and Vaccine Immunology. 2014 ; Vol. 21, No. 11. pp. 1528-1533.
@article{0a15d2508c324d6f8b99a39f8a46bced,
title = "Adeno-associated virus 9-mediated airway expression of antibody protects old and immunodeficient mice against influenza virus",
abstract = "Influenza causes serious and sometimes fatal disease in individuals at risk due to advanced age or immunodeficiencies. Despite progress in the development of seasonal influenza vaccines, vaccine efficacy in elderly and immunocompromised individuals remains low. We recently developed a passive immunization strategy using an adeno-associated virus (AAV) vector to deliver a neutralizing anti-influenza antibody at the site of infection, the nasal airways. Here we show that young, old, and immunodeficient (severe combined immunodeficient [SCID]) mice that were treated intranasally with AAV9 vector expressing a modified version of the broadly neutralizing anti-influenza antibody FI6 were protected and exhibited no signs of disease following an intranasal challenge with the mouse-adapted H1N1 influenza strain A/Puerto Rico/8/1934(H1N1) (PR8) (Mt. Sinai strain). Nonvaccinated mice succumbed to the PR8 challenge due to severe weight loss. We propose that airway-directed AAV9 passive immunization against airborne infectious agents may be beneficial in elderly and immunocompromised patients, for whom there still exists an unmet need for effective vaccination against influenza.",
author = "Adam, {Virginie S.} and Marco Crosariol and Sachin Kumar and Ge, {Moyar Q.} and Czack, {Sarah E.} and Soumitra Roy and Haczku, {Angela Franciska} and Anna Tretiakova and Wilson, {James M.} and Limberis, {Maria P.}",
year = "2014",
month = "11",
day = "1",
doi = "10.1128/CVI.00572-14",
language = "English (US)",
volume = "21",
pages = "1528--1533",
journal = "Clinical and Vaccine Immunology",
issn = "1556-6811",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - Adeno-associated virus 9-mediated airway expression of antibody protects old and immunodeficient mice against influenza virus

AU - Adam, Virginie S.

AU - Crosariol, Marco

AU - Kumar, Sachin

AU - Ge, Moyar Q.

AU - Czack, Sarah E.

AU - Roy, Soumitra

AU - Haczku, Angela Franciska

AU - Tretiakova, Anna

AU - Wilson, James M.

AU - Limberis, Maria P.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Influenza causes serious and sometimes fatal disease in individuals at risk due to advanced age or immunodeficiencies. Despite progress in the development of seasonal influenza vaccines, vaccine efficacy in elderly and immunocompromised individuals remains low. We recently developed a passive immunization strategy using an adeno-associated virus (AAV) vector to deliver a neutralizing anti-influenza antibody at the site of infection, the nasal airways. Here we show that young, old, and immunodeficient (severe combined immunodeficient [SCID]) mice that were treated intranasally with AAV9 vector expressing a modified version of the broadly neutralizing anti-influenza antibody FI6 were protected and exhibited no signs of disease following an intranasal challenge with the mouse-adapted H1N1 influenza strain A/Puerto Rico/8/1934(H1N1) (PR8) (Mt. Sinai strain). Nonvaccinated mice succumbed to the PR8 challenge due to severe weight loss. We propose that airway-directed AAV9 passive immunization against airborne infectious agents may be beneficial in elderly and immunocompromised patients, for whom there still exists an unmet need for effective vaccination against influenza.

AB - Influenza causes serious and sometimes fatal disease in individuals at risk due to advanced age or immunodeficiencies. Despite progress in the development of seasonal influenza vaccines, vaccine efficacy in elderly and immunocompromised individuals remains low. We recently developed a passive immunization strategy using an adeno-associated virus (AAV) vector to deliver a neutralizing anti-influenza antibody at the site of infection, the nasal airways. Here we show that young, old, and immunodeficient (severe combined immunodeficient [SCID]) mice that were treated intranasally with AAV9 vector expressing a modified version of the broadly neutralizing anti-influenza antibody FI6 were protected and exhibited no signs of disease following an intranasal challenge with the mouse-adapted H1N1 influenza strain A/Puerto Rico/8/1934(H1N1) (PR8) (Mt. Sinai strain). Nonvaccinated mice succumbed to the PR8 challenge due to severe weight loss. We propose that airway-directed AAV9 passive immunization against airborne infectious agents may be beneficial in elderly and immunocompromised patients, for whom there still exists an unmet need for effective vaccination against influenza.

UR - http://www.scopus.com/inward/record.url?scp=84914671395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84914671395&partnerID=8YFLogxK

U2 - 10.1128/CVI.00572-14

DO - 10.1128/CVI.00572-14

M3 - Article

C2 - 25209558

AN - SCOPUS:84914671395

VL - 21

SP - 1528

EP - 1533

JO - Clinical and Vaccine Immunology

JF - Clinical and Vaccine Immunology

SN - 1556-6811

IS - 11

ER -